65,437 trials
Reproductive Sterility
Primary: Number of Control and Treated Participants With Successful Live Births Following Conventional IVF or ICSI Cycles — 18; 13; 8; 9 participants
Dermatitis, Photoallergic
Primary: Photoallergic Reaction Evaluation Reported as Number of Test Site With Different Erythema Score During Challenge Phase - All Treated Subjects — 325; 24; 343; 6 Test site
End Stage Renal Disease
Primary: Pharmacokinetics (PK) of Triferic Iron Administered Via Hemodialysate in Adult CKD-5HD Patients: Cmax. — 207 h*ug/dL
Diabetes Mellitus
Primary: Area Under the Curve (AUC) of Plasma Total GLP-1 Levels After Intake of the Study Meal — 10.5; 10.5 pM x hr/L
Glaucoma
Primary: Mean Change in Intraocular Pressure Between Two Measures- Baseline and 3 Months — -2.3; -6.4 mmHg
Metastatic Pancreatic Adenocarcinoma
Primary: Progression Free Survival (PFS) — 5.32; 6.01 Months — p=<0.0001
Type 2 Diabetes · Depression
Primary: Change of Glycated Hemoglobin A1c (Hb A1c) After the Cognitive Behavioral Therapy Sessions — 7.70; 8.42 percent
Lymphoma
Primary: Number of Participants With Overall Survival (10 Years) by Treatment — 59; 58 Participants
Waldenström's Macroglobulinemia
Primary: Progression Free Survival (PFS) Based on Independent Review Committee (IRC) Assessment - Kaplan Meier Landmark Estimates at Month 54 — 68.0; 25.3; 39.7 percentage of…
Neuropathic Diabetic Ulcer - Foot
Primary: Number of Participants Experiencing Adverse Events — 20 Participants
Breast Cancer
Primary: Safety
Congestive Heart Failure Treated
Primary: Combined Endpoint on Patient Clinical Outcome
Acne Vulgaris
Primary: Investigator's Global Assessment (IGA) "Success" - Week 12 — 5; 3; 2; 6 Participants
Autism Spectrum Disorder
Primary: Efficacy of Intranasal Oxytocin vs. Placebo on Measures of Social Function — -2.43; -3.06; -1.34; -3.03 units on a scale
Acne
Primary: Mean Percent Change From Baseline in Inflammatory (Papules and Pustules) Lesions — 71.05; 72.84; 51.53 percentage of lesion change